Haisike announced that its subsidiary Tibet Haisike Pharmaceutical Co., Ltd. recently received the "Notice of Approval for Drug Clinical Trial" issued by the State Food and Drug Administration. HSK46575 tablets are an oral, potent and highly selective small molecule inhibitor intended for the treatment of prostate cancer. Preclinical study results show that this product has a clear target, definite efficacy and good safety. It is a small molecule drug with great development potential, a high benefit/risk ratio in clinical application, and broad clinical application prospects. It is expected to become an effective treatment for prostate cancer and solve the current problem of lack of clinical drugs.